INTRODUCTION
============

OA is the most prevalent form of arthropathy, the incidence of which increases with age, affecting around 50% of the aged population ([@b17-molce-38-8-677]; [@b62-molce-38-8-677]). OA is primarily characterized by structural damage and functional failure of articular cartilage. Cartilage homeostasis is maintained by chondrocytes, a unique cell type resident in cartilage. Chondrocytes express various extracellular matrix (ECM) molecules such as type II collagen and sulfated proteoglycans, which are essential components of chondrocyte anabolism ([@b56-molce-38-8-677]; [@b63-molce-38-8-677]). Dense aggregates of negatively charged proteoglycans attract water molecules and promote osmotic swelling, endowing the tissue with resistance to compressive loading. A network of cross-linked collagen fibrils, in contrast, provides tensile resistance and counterbalances this osmotic swelling, imparting tissue integrity and load-bearing properties to articular cartilage.

OA chondrocytes, on the other hand, are characterized by accelerated catabolic processes as well as suppression of anabolic processes. Upregulation of matrix-degrading enzymes such as matrix metalloproteinases (MMPs), and a disintegrin and metalloproteinases with thrombospondin motifs (ADAMTS) family drives degradation of cartilage ECM, eventually leading to cartilage destruction ([@b39-molce-38-8-677]; [@b54-molce-38-8-677]). Inflammatory mediators such as COX2 and NO further contribute to eliciting imbalance between chondrocyte catabolism and anabolism ([@b44-molce-38-8-677]).

Various etiological factors for OA have been noted, including those unrelated to genetics, such as age, obesity, dietary factors, sedentary life style, and injury ([@b3-molce-38-8-677]; [@b66-molce-38-8-677]; [@b100-molce-38-8-677]). However, the precise molecular and cellular mechanisms by which these environmental OA risk factors mediate the disruption of cartilage homeostasis remain elusive. Recent progress in elucidating the epigenetic regulation of chondrocyte catabolism and anabolism has shed light on the molecular pathogenesis of OA.

TYPES OF EPIGENETIC REGULATION IN CHONDROCYTES
==============================================

DNA methylation
---------------

DNA methylation, which is associated with the remodeling of chromatin structure, plays an essential role in regulating gene expression. The alteration of chromatin structure induced by DNA methylation blocks the access of transcriptional machineries to the promoter regions of target genes and facilitates the recruitment of repressive chromatin remodeling complexes, collectively causing transcriptional repression ([@b85-molce-38-8-677]). DNA methylation patterns are regulated by several different DNA methyltransferases (DNMTs) such as DNMT1, DNMT3A, and DNMT3B ([@b83-molce-38-8-677]). In fact, DNMT1 and DNMT3A are present at high levels in cartilage tissue, suggesting possible roles for these enzymes in the regulation of chondrocyte homeostasis ([@b93-molce-38-8-677]). However, it was reported that there is no apparent change in the overall DNA methylation content in chondrocytes isolated from OA patients ([@b93-molce-38-8-677]). Instead, DNA methylation patterns in OA chondrocytes exhibit dynamic alterations when examined at the promoter regions of individual genes ([@b22-molce-38-8-677]).

In OA, inflammatory cytokines such as IL-1β promote the expression of matrix-degrading enzymes ([@b96-molce-38-8-677]). Demethylation of CpG sites within the *IL1B* promoter is required for the expression of this gene in OA-like conditions ([@b36-molce-38-8-677]; [@b37-molce-38-8-677]). In addition, the promoters of genes encoding catabolic factors such as MMP3, 9, 13, and ADAMTS4 are demethylated, accounting for the increased expression of these genes under OA-related pathogenic conditions ([@b87-molce-38-8-677]). Notably, the methylation status of the *MMP13* promoter region modulates the access and binding of hypoxia-inducible factor (HIF)-2α ([@b37-molce-38-8-677]), which is a master regulator of chondrocyte catabolism ([@b90-molce-38-8-677]; [@b102-molce-38-8-677]), adding an extra layer of transcriptional regulation of *MMP13*. Furthermore, hypomethlyation of the *MMP13* promoter exposes the binding region for cAMP response element-binding protein (CREB) and CREB binding protein (CBP), resulting in increased *MMP13* expression ([@b4-molce-38-8-677]).

Similarly, DNA methylation influences the expression levels of anabolic factors during the pathogenesis of OA. Hypermethylation of the *COL9A1* enhancer causes transcriptional repression of *COL9A1* during OA development by attenuating the binding of SOX9 to the *COL9A1* promoter ([@b47-molce-38-8-677]; [@b108-molce-38-8-677]). In contrast, the expression of *COL2A1* and *ACAN* do not appear to be affected by the methylation status of CpG sites on their promoters ([@b47-molce-38-8-677]; [@b82-molce-38-8-677]; [@b108-molce-38-8-677]). Alteration of methylation patterns may be accompanied by single nucleotide polymorphisms (SNP), accounting for genetic susceptibility to OA. For instance, there are two SNP sites (rs143383 and rs143384) in the 5′UTR of *GDF5*, whose roles in joint development and chondroprotection are well-characterized ([@b86-molce-38-8-677]). The disease-associated T allele, arising as a result of a SNP (rs143384, C/T) in *GDF5* is linked to susceptibility to OA, putatively associated with the aberrant demethylated state of its promoter ([@b86-molce-38-8-677]).

Histone modification
--------------------

The post-translational modification of histones includes acetylation, methylation, ubiquitination, sumoylation, and phosphorylation. The overall pattern of histone modification regulates interaction between DNA, regulatory proteins, and other histone molecules, thereby affecting gene expression ([@b59-molce-38-8-677]).

Histone N-terminal tails protruding from nucleosomes are subjected to acetylation modifications by histone acetyltransferases (HATs), which include three major families: Gcn5 N-acetyltransferases (GNATs), p300/CBP, and MYST family (named for its founder members Morf, Ybf2, Sas2, and Tip60) ([@b94-molce-38-8-677]). Histone acetylation mediated by p300/CBP leads to transcriptional activation of *SOX9*, illustrating the role of the HAT family in sustaining chondrocyte homeostasis ([@b25-molce-38-8-677]; [@b26-molce-38-8-677]).

Histone deacetylases (HDACs), in contrast, oppose the action of HAT enzymes by removing the acetyl group from lysine residues. HDACs are subdivided into two groups: The SIR2 family of NAD^+^-dependent protein deacetylases and the classical HDAC family. The SIR2 family, consisting of seven family members in mammals (SIRT1-7), removes acetyl groups from lysine residues of histones H3 and H4, and non-histone proteins ([@b1-molce-38-8-677]; [@b16-molce-38-8-677]). In chondrocytes, SIRT1, one of the most extensively studied SIRT family members, was shown to promote the expression of cartilage-specific genes in a SOX9-dependent manner ([@b20-molce-38-8-677]). SIRT1 forms a complex with SOX9 and targets it for deacetylation. The complex is subsequently brought to the enhancer and promoter regions of *COL2A1*, where it further recruits coactivators such as GCN5, PGC1α, and p300, modulating the acetylation state of H3K9/K14 and H4K5, and mediating tri-methylation of H3K4 ([@b20-molce-38-8-677]). In line with reports revealing the anabolic roles of SIRT1 in chondrocytes, other chondroprotective roles of SIRT1 have been noted in the context of OA pathogenesis. SIRT1 suppresses protein tyrosine phosphatase 1B (PTP1B) and activates insulin-like growth factor (IGF) receptor pathway, enhancing survival of chondrocytes ([@b29-molce-38-8-677]). Moreover, TNFα signaling triggers cathepsin B-mediated cleavage of SIRT1, producing 75-kDa SIRT1 ([@b21-molce-38-8-677]). This 75-kDa SIRT1 has been shown to be implicated in protecting chondrocytes from apoptosis following exposure to proinflammatory cytokines ([@b77-molce-38-8-677]). Consistently, heterozygous haploinsufficient *Sirt1^+/^*^−^ or *Sirt1* mutant mice lacking SIRT1 enzymatic activity show increased chondrocyte apoptosis and enhanced OA severity with age ([@b27-molce-38-8-677]; [@b28-molce-38-8-677]; [@b69-molce-38-8-677]). Furthermore, the expression level of SIRT1 is reduced over the course of OA, giving rise to hypertrophic phenotypes and OA-like gene expression patterns in chondrocytes ([@b24-molce-38-8-677]). Similarly, surgically-induced OA pathogenesis in mice was significantly accelerated by chondrocyte-specific deletion of the *Sirt1* gene, with concomitant downregulation of anabolic proteins and upregulation of cartilage degrading enzymes ([@b28-molce-38-8-677]; [@b69-molce-38-8-677]). Moreover, in *Sirt1* CKO mice, p65 was found to be acetylated, which in turn causes activation of NF-κB pathway and consequently catabolic pathways, augmenting OA pathogenesis ([Fig. 1](#f1-molce-38-8-677){ref-type="fig"}) ([@b21-molce-38-8-677]). Additionally, SIRT6 has been shown to be responsible for controlling senescence in cartilage by protecting chondrocytes from DNA damage, telomere dysfunction, and premature senescence ([@b73-molce-38-8-677]).

Classical HDACs remove acetyl groups from N-acetyl lysine residues on histones, enabling the histones to wrap DNA more tightly to repress transcription. The broad inhibition of HDACs by trichostatin A (TSA) or PXD101 was shown to suppress *COL2A1* expression in chondrocytes, suggesting that the HDAC family plays a role in regulating chondrocyte anabolism. Moreover, HDAC inhibition promotes acetylation of the *WNT-5A* promoter, which in turn leads to transcriptional suppression of *COL2A1* ([@b45-molce-38-8-677]). HDAC1 and HDAC2 activity were found to be responsible for the transcriptional repression of cartilage-specific genes through the activation of NF-κB signaling ([@b41-molce-38-8-677]; [@b105-molce-38-8-677]). HDAC4 was identified as a core element regulating hypertrophic maturation of chondrocytes and endochondral bone formation. HDAC4 not only suppresses the expression of RUNX2 at the transcriptional level via interaction with histones, but also interacts with RUNX2 directly, reducing its transcriptional activity ([@b97-molce-38-8-677]). HDAC7, on the other hand, plays a role in the regulation of chondrocyte catabolism. HDAC7 activity is markedly upregulated in OA cartilage, and essentially required for IL-1β-mediated expression of MMP13 ([@b40-molce-38-8-677]).

HDACs generally augment imbalance between catabolism and anabolism in chondrocytes, and the potential of HDAC inhibitors as therapeutic agents for OA treatment have been extensively investigated. TSA, butyric acid (BA), and vorinostat treatment have been shown to effectively diminish IL-1-mediated expression of inducible nitric oxide (NO) synthase (iNOS), COX2, and MMPs ([@b10-molce-38-8-677]; [@b106-molce-38-8-677]). These anti-inflammatory effects of HDAC inhibitors were demonstrated in vivo, with concomitant suppression of osteoarthritic cartilage destruction and synovitis ([@b74-molce-38-8-677]).

Meanwhile, histone methylation is mediated by histone methyl transferases (HMTs). Methylation can occur on both lysine and arginine residues in histones without altering the net charge of the affected residues. SOX9, a transcriptional regulator of *COL2A1* and *ACAN*, is itself subjected to progressive epigenetic regulation over the course of OA progression. Under OA-related pathogenic conditions, the promoter of *SOX9* acquires a epigenetic profile characterized by elevated levels of trimethylation of H3K9 and H3K27, and decreased acetylation of H3K9, 15, 18, 23, and 27, which collectively leads to transcriptional repression of *SOX9* ([@b53-molce-38-8-677]). Histone-lysine N-methyltransferase SETD7 (SET7/9) forms a complex with SIRT1 in the *COL2A1* promoter region and elevates trimethylation of H3K4, thereby enhancing *COL2A1* expression ([@b78-molce-38-8-677]). Nuclear factor of activated T-cells 1 (NFAT1) is a transcription factor whose deficiency is correlated with the onset of OA-related phenotypes ([@b98-molce-38-8-677]). Age-dependent expression of NFAT1 is primarily regulated by histone demethylation. Demethylation at H3K4 by lysine-specific demethylase-1A (LSD1) appears to be associated with transcriptional activation of NFAT1 during cartilage development, whereas an aging-associated increase in H3K9 methylation due to reduced lysine-specific demethylase 3A (KDM3A) level is responsible for transcriptional repression of NFAT1 ([@b88-molce-38-8-677]).

EPIGENETIC EFFECTS OF OA RISK FACTORS
=====================================

Aging-associated ROS
--------------------

The increasing prevalence of OA in aging individuals supports the possibility that aging-associated events have causal effects on epigenetic drift, driving catabolic and anabolic imbalance in chondrocytes. Age-associated increase of oxidative stress, indicated by elevated reactive oxygen species (ROS) level, has been noted in chondrocytes ([@b8-molce-38-8-677]; [@b50-molce-38-8-677]). Overall ROS level is controlled by the collective actions of enzymes such as glutathione peroxidase, superoxide dismutase, and catalase in normal chondrocytes. However, the senescence of chondrocytes disrupts this delicate balance between ROS generation and its defense mechanisms, resulting in an elevation in ROS level ([@b89-molce-38-8-677]). An increase in ROS levels, in turn, has been shown to affect the stability and activity of histone modifying enzymes. ROS induce covalent modification of SIRT1 by carbonylating it on the thiol groups of cysteine residues between amino acid residues 467 and 492 ([@b6-molce-38-8-677]). Carbonylated SIRT1 exhibits reduced protein stability, presumably becoming associated with the ubiquitin-mediated proteasome degradation pathway ([@b48-molce-38-8-677]). Moreover, carbonylation of SIRT1 also occurs on the NAD^+^ binding pocket, thereby reducing its enzymatic activity ([@b6-molce-38-8-677]). HDAC proteins are also a target of carbonylation under oxidative stress conditions. Oxidative stress generates 4-hydroxy-2-nonenal (4-HNE) and acrolein, which in turn react with histidine groups of HDAC2. This covalent modification in HDAC2 is responsible for reducing its protein stability ([@b68-molce-38-8-677]). Nitration also acts as a mediator, linking oxidative stress levels to HDAC2 regulation. The identified nitration sites in HDAC2 include Y167, Y173, Y146, Y68, Y73, and Y253, and nitration on the Y253 residue primes HDAC2 for the proteasome pathway ([@b79-molce-38-8-677]).

Aging-associated production of ROS elicits DNA damage, which in turn triggers activation of DNA repair mechanisms. In line with evidence indicating a role for DNA methylation in repairing processes, DNMT1 and DNMT3A were shown to be recruited to the sites of DNA damage, where they methylate neighboring CpG sites ([@b71-molce-38-8-677]), potentially causing hypermethylation of the CpG sites, which results in suppression of gene expression.

Metabolites and obesity
-----------------------

Epigenetic modifications such as acetylation, methylation, and glycosylation are influenced by the intracellular metabolic state. By altering epigenetic profiles, cells respond to metabolic challenges and adapt to it by subsequently changing intracellular signal transduction and gene expression ([@b70-molce-38-8-677]).

Oxygen levels in the joint environment substantially affect energy and metabolic state of chondrocytes, influencing catabolic and anabolic factor expression ([@b91-molce-38-8-677]). In particular, in articular cartilage which is under hypoxic conditions due to its avascular nature, HIF-1α may serve as an epigenetic mediator by directly inducing SIRT1 expression and activating SIRT1-driven epigenetic programs ([@b13-molce-38-8-677]).

Metabolites from cellular metabolic pathways may act as sensors of energy state, and mediate corresponding epigenetic changes. Acetyl-CoA, a component of the tricarboxylic acid (TCA) cycle and an essential building block for key metabolic biomolecules, can also serve as a substrate for HATs ([@b51-molce-38-8-677]). Consequently, the intracellular acetyl-CoA level determines the acetylation patterns of lysine residues as a measure of metabolic state, regulating cell growth and proliferation ([@b5-molce-38-8-677]). Moreover, the activity of ATP-citrate lyase (ACL), which is an enzyme synthesizing acetyl-CoA from glucose-derived citrate in mammals, depends on glucose abundance. Therefore, ACL is capable of serving as a nutrient sensor, linking intracellular energy state into histone acetylation and gene expression profiles ([@b38-molce-38-8-677]; [@b99-molce-38-8-677]).

Methyltransferases use S-adenosylmethionine (SAM), derived from the methionine cycle, as a methyl group donor. The production rate of SAM is regulated by the activity of ATP-dependent methionine adenosyltransferase (MAT). Thus, cellular ATP controls the intracellular level of SAM and the activity of various methyltransferases, in turn influencing transcription profiles ([@b75-molce-38-8-677]). Many other enzymes regulating epigenetic changes use biological metabolites such as NAD^+^ (protein deacetylase/mono-ADP ribosyltransferase, and sirtuin), FAD (FAD-dependent histone demethylase), and 2-oxoglutarate (2-oxoglutarate-dependent histone demethylase) as cofactors, or UDP-N-acetylglucosamine (O-linked N-acetylglucosamine transferase) as a substrate.

The effect of metabolites on epigenetic regulation supports the link between metabolism and the molecular pathogenesis of various diseases ([@b51-molce-38-8-677]). SIRT family members have been demonstrated to be key metabolic regulators in controlling glucose and lipid metabolism ([@b81-molce-38-8-677]; [@b92-molce-38-8-677]), and gluconeogenesis in muscle and liver ([@b65-molce-38-8-677]). SIRT1 promotes insulin secretion and ATP production upon glucose stimulation of pancreatic β cells ([@b2-molce-38-8-677]). In metabolic syndrome patients with insulin resistance or atherosclerosis, downregulation of SIRT1 was observed in monocytes in response to glucose or fatty acid treatment ([@b15-molce-38-8-677]). Isoforms of the HDAC family are implicated in regulating lipid metabolism during adipogenesis ([@b49-molce-38-8-677]). Genetic deletion of *Hdac1* and *Hdac2* in mesenchymal precursor cells results in reduced adipogenesis and adipocyte differentiation, ([@b34-molce-38-8-677]), while *Hdac9* knockout mice exhibited accelerated adipogenic differentiation ([@b11-molce-38-8-677]). Protein demethylase KDM3A is coupled to the regulation of genes involved in beta-adrenergic stimulated glycerol release and fatty acid oxidation such as uncoupling protein 1 (UCP1) ([@b95-molce-38-8-677]). Extensive correlation between epigenetics and abnormal metabolic state have been noted in metabolic diseases such as obesity ([@b7-molce-38-8-677]) and type 2 diabetes ([@b7-molce-38-8-677]; [@b64-molce-38-8-677]).

There has been substantial evidence for the idea that the prevalence of OA is positively correlated with that of metabolic syndrome ([Table 1](#t1-molce-38-8-677){ref-type="table"}) ([@b57-molce-38-8-677]; [@b84-molce-38-8-677]; [@b107-molce-38-8-677]). Among the main features of metabolic syndrome, obesity has been considered to be a major risk factor for OA occurrence in the joints of knees, hip, and hands ([@b31-molce-38-8-677]; [@b76-molce-38-8-677]). However, a mechanistic understanding of the association between obesity and OA remains elusive. The simplest view indicates that obesity exacerbates joint strength by imposing a higher degree of mechanical loading on the joint ([@b33-molce-38-8-677]). Clinical studies have supported the idea that abnormal loading jeopardizes the structure and integrity of the knee joint, facilitating OA development ([@b67-molce-38-8-677]; [@b72-molce-38-8-677]). However, the notion that mechanical loading is the sole factor for obesity-induced OA is controversial. A series of studies demonstrate that the incidence and severity of hand OA have a positive correlation with body mass index (BMI), although mechanical loading from body weight cannot participate in the pathogenesis of this type of OA ([@b9-molce-38-8-677]).

Adipokines released from fat tissues may represent a potential link between obesity and OA. Strikingly, obese mice with impairment in leptin signaling, due to deletion of leptin or leptin receptor, do not exhibit differences in terms of severity of OA in comparison to mice with normal body weight ([@b32-molce-38-8-677]). In fact, synovial fluid of OA patients was characterized to have elevated levels of leptin ([@b19-molce-38-8-677]; [@b60-molce-38-8-677]). Increased levels of leptin in synovial fluid and cartilage promote cartilage catabolism by upregulating *MMP13* and *NOS2* expression ([@b46-molce-38-8-677]; [@b80-molce-38-8-677]).

Other adipokines, such as adiponectin ([@b12-molce-38-8-677]; [@b61-molce-38-8-677]) and visfatin, ([@b18-molce-38-8-677]) were found to be responsible for the regulation of chondrocyte metabolism. Adiponectin is known to regulate homeostasis of whole body energy by controlling glucose and lipid metabolism, and abnormalities in its regulation have been implicated in several metabolic disorders including obesity ([@b55-molce-38-8-677]). While alterations of adiponectin level were noted in OA cartilage and synovial fluid ([@b43-molce-38-8-677]; [@b58-molce-38-8-677]; [@b104-molce-38-8-677]), the role of this adipokine in OA development remains controversial. A study by Kang and colleagues suggests that that adiponectin promotes chondrocyte catabolism by upregulating MMPs and NOS2 levels via AMPK and JNK pathways ([@b52-molce-38-8-677]). Others have suggested a chondroprotective function for adiponectin, demonstrating its role in upregulating inhibition of metalloproteinase 2 (TIMP2) and downregulating MMP13 ([@b12-molce-38-8-677]; [@b104-molce-38-8-677]). Visfatin (encoded by *NAMPT*) is an adipokine that has been found to be upregulated in chondrocytes, synovial fluid, and synoviocytes on OA. Visfatin inhibits matrix proteoglycan synthesis and increases the expression of matrix-degradative enzymes ([@b18-molce-38-8-677]; [@b30-molce-38-8-677]; [@b101-molce-38-8-677]; [@b103-molce-38-8-677]). Notably, visfatin can be localized intracellularly, serving as a regulator of salvage pathways of NAD^+^ synthesis. Increased level of NAD^+^ by intracellular visfatin enhances enzymatic activity of SIRT1, affecting the expression of SOX9 and type II collagen through epigenetic regulation ([@b42-molce-38-8-677]).

In addition to obese individuals, patients with hypertension are highly likely to suffer from OA ([@b14-molce-38-8-677]; [@b35-molce-38-8-677]). Hypertension triggers the onset of subchondral ischemia, which is considered to promote the pathogenesis of OA, by restricting the formation of subchondral vessels and limiting nutrient and gas support to cartilage ([@b23-molce-38-8-677]). Hypertension is presumed to affect a subset of epigenetic pathways that are regulated by glucose or oxygen in cartilage.

CONCLUSION
==========

The recognition of non-genetic factors, such as aging or obesity, as principal risk factors for OA has highlighted the potential significance of epigenetics in the pathogenesis of this disease ([Fig. 2](#f2-molce-38-8-677){ref-type="fig"}). A series of studies reviewed in this paper indicate that various types of epigenetic drift at the level of DNA methylation or histone modification are implicated in regulating chondrocyte catabolism and anabolism, over the course of OA development. These epigenetic regulations in chondrocytes are substantially affected by cellular senescence, or energy and metabolic state. Moreover, the close correlation between the occurrence of OA and metabolic disorders supports the idea that OA is a metabolic disease. Animal studies targeting the components of epigenetic regulators have demonstrated the potential of these compounds as therapeutic options for OA treatment. Rapid advances in molecular biology techniques, such as epigenome sequencing and ChIP technologies, are expected to lead to a more comprehensive understanding of epigenetic regulation in the pathogenesis of OA.
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![Epigenetic regulation of chondrocyte anabolism and apoptosis by SIRT1. SIRT1 forms a complex with SET7/9 or SOX9 and recruits HATs, facilitating acetylation of the *COL2A1* promoter and expression of *COL2A1*. SIRT1 inhibits chondrocyte apoptosis by suppressing PTP1B or activating IGF pathway. TNFα-mediated generation of 75-kDa SIRT1 inhibits inflammation-induced apoptosis. Downregulation of SIRT1 in OA is responsible for suppression of chondrocyte anabolism and increased apoptosis.](molce-38-8-677f1){#f1-molce-38-8-677}

![Overview of epigenetic regulation in OA pathogenesis. OA-associated risk factors such as aging (senescence) and metabolic abnormalities drive epigenetic shift at the level of DNA methylation and histone modification. These epigenetic changes elicit an imbalance between chondrocyte catabolism and anabolism, leading to OA development.](molce-38-8-677f2){#f2-molce-38-8-677}

###### 

Effect of aging and metabolic abnormalities on OA progression

  Risk factors         Mediators                                       Progression of OA                                                                              Reference
  -------------------- ----------------------------------------------- ---------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  Aging (Senescence)   Reactive oxygen species                         Increase                                                                                       [@b6-molce-38-8-677]; [@b48-molce-38-8-677]; [@b68-molce-38-8-677]; [@b79-molce-38-8-677]
  Obesity              Mechanical loading                              Increase                                                                                       [@b33-molce-38-8-677]; [@b67-molce-38-8-677]; [@b72-molce-38-8-677]
  No effect            [@b9-molce-38-8-677]                                                                                                                           
  Adipokine            Leptin                                          Increase                                                                                       [@b46-molce-38-8-677]; [@b80-molce-38-8-677]
  Adiponectin          Increase                                        [@b52-molce-38-8-677]                                                                          
  Decrease             [@b12-molce-38-8-677]; [@b104-molce-38-8-677]                                                                                                  
  Visfatin             Increase                                        [@b18-molce-38-8-677]; [@b30-molce-38-8-677]; [@b101-molce-38-8-677]; [@b103-molce-38-8-677]   
  Hypertension         Subchondral ischemia                            Increase                                                                                       [@b42-molce-38-8-677]
